Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease

Raquel Figuinha Videira; Paula A. da Costa Martins; Ines Falcao-Pires

doi:10.3390/ijms21239285

Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease

Raquel Figuinha Videira, Paula A. da Costa Martins, Ines Falcao-Pires^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

8 Citations (Web of Science)

Abstract

In 2020, cardiovascular diseases (CVDs) remain a leading cause of mortality and morbidity, contributing to the burden of the already overloaded health system. Late or incorrect diagnosis of patients with CVDs compromises treatment efficiency and patient's outcome. Diagnosis of CVDs could be facilitated by detection of blood-based biomarkers that reliably reflect the current condition of the heart. In the last decade, non-coding RNAs (ncRNAs) present on human biofluids including serum, plasma, and blood have been reported as potential biomarkers for CVDs. This paper reviews recent studies that focus on the use of ncRNAs as biomarkers of CVDs.

Original language	English
Article number	9285
Number of pages	20
Journal	International journal of molecular sciences
Volume	21
Issue number	23
DOIs	https://doi.org/10.3390/ijms21239285
Publication status	Published - Dec 2020

Keywords

ncRNAs
biomarkers
cardiovascular diseases
diagnosis
NONINVASIVE BIOMARKERS
MYOCARDIAL-INFARCTION
CORONARY ATHEROSCLEROSIS
PRENATAL DETECTION
PROGNOSTIC VALUE
HEART-FAILURE
CIRCULAR RNAS
PLASMA
DIAGNOSIS
MICRORNAS

Access to Document

10.3390/ijms21239285Licence: CC BY

Cite this

@article{ceb8a9787d194511abd519faf566a0d4,

title = "Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease",

abstract = "In 2020, cardiovascular diseases (CVDs) remain a leading cause of mortality and morbidity, contributing to the burden of the already overloaded health system. Late or incorrect diagnosis of patients with CVDs compromises treatment efficiency and patient's outcome. Diagnosis of CVDs could be facilitated by detection of blood-based biomarkers that reliably reflect the current condition of the heart. In the last decade, non-coding RNAs (ncRNAs) present on human biofluids including serum, plasma, and blood have been reported as potential biomarkers for CVDs. This paper reviews recent studies that focus on the use of ncRNAs as biomarkers of CVDs.",

keywords = "ncRNAs, biomarkers, cardiovascular diseases, diagnosis, NONINVASIVE BIOMARKERS, MYOCARDIAL-INFARCTION, CORONARY ATHEROSCLEROSIS, PRENATAL DETECTION, PROGNOSTIC VALUE, HEART-FAILURE, CIRCULAR RNAS, PLASMA, DIAGNOSIS, MICRORNAS",

author = "Videira, {Raquel Figuinha} and Martins, {Paula A. da Costa} and Ines Falcao-Pires",

year = "2020",

month = dec,

doi = "10.3390/ijms21239285",

language = "English",

volume = "21",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "23",

}

TY - JOUR

T1 - Non-Coding RNAs as Blood-Based Biomarkers in Cardiovascular Disease

AU - Videira, Raquel Figuinha

AU - Martins, Paula A. da Costa

AU - Falcao-Pires, Ines

PY - 2020/12

Y1 - 2020/12

N2 - In 2020, cardiovascular diseases (CVDs) remain a leading cause of mortality and morbidity, contributing to the burden of the already overloaded health system. Late or incorrect diagnosis of patients with CVDs compromises treatment efficiency and patient's outcome. Diagnosis of CVDs could be facilitated by detection of blood-based biomarkers that reliably reflect the current condition of the heart. In the last decade, non-coding RNAs (ncRNAs) present on human biofluids including serum, plasma, and blood have been reported as potential biomarkers for CVDs. This paper reviews recent studies that focus on the use of ncRNAs as biomarkers of CVDs.

AB - In 2020, cardiovascular diseases (CVDs) remain a leading cause of mortality and morbidity, contributing to the burden of the already overloaded health system. Late or incorrect diagnosis of patients with CVDs compromises treatment efficiency and patient's outcome. Diagnosis of CVDs could be facilitated by detection of blood-based biomarkers that reliably reflect the current condition of the heart. In the last decade, non-coding RNAs (ncRNAs) present on human biofluids including serum, plasma, and blood have been reported as potential biomarkers for CVDs. This paper reviews recent studies that focus on the use of ncRNAs as biomarkers of CVDs.

KW - ncRNAs

KW - biomarkers

KW - cardiovascular diseases

KW - diagnosis

KW - NONINVASIVE BIOMARKERS

KW - MYOCARDIAL-INFARCTION

KW - CORONARY ATHEROSCLEROSIS

KW - PRENATAL DETECTION

KW - PROGNOSTIC VALUE

KW - HEART-FAILURE

KW - CIRCULAR RNAS

KW - PLASMA

KW - DIAGNOSIS

KW - MICRORNAS

U2 - 10.3390/ijms21239285

DO - 10.3390/ijms21239285

M3 - Review article

C2 - 33291434

VL - 21

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 23

M1 - 9285

ER -